Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease

被引:1
|
作者
Lansdall, Claire J. [1 ]
Teng, Edmond [2 ]
Chague, Jerome [3 ]
Palanganda, Rohan [4 ]
Delmar, Paul [3 ]
Smith, Janice [5 ]
Cummings, Jeffrey L. [6 ]
McDougall, Fiona [7 ]
机构
[1] F Hoffmann La Roche Ltd, Prod Dev, Patient Ctr Outcomes Res, Basel, Switzerland
[2] Genentech Inc, Early Clin Dev, South San Francisco, CA USA
[3] F Hoffmann La Roche Ltd, Prod Dev, Data Sci, Basel, Switzerland
[4] Roche Prod Ltd, Prod Dev, Data Sci, Welwyn Garden City, England
[5] Roche Prod Ltd, Prod Dev, Neurosci, Welwyn Garden City, England
[6] Univ Nevada, Chambers Grundy Ctr Transformat Neurosci, Las Vegas, NV USA
[7] Genentech Inc, Prod Dev, Patient Ctr Outcomes Res, South San Francisco, CA USA
关键词
activities of daily living; Alzheimer's disease; anchor-based; Caregiver Global Impression of Change - Alzheimer's Disease; Clinical Dementia Rating-Sum of Boxes; clinical meaningfulness; cognition; function; meaningful change; mild dementia due to Alzheimer's disease; mild cognitive impairment due to Alzheimer's disease; Tauriel; DIAGNOSTIC-CRITERIA; EDUCATION; ASSOCIATION; CORTEX; MEMORY; BRAIN; RISK;
D O I
10.1002/alz.14050
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION: Consensus definitions of meaningful within-patient change (MWPC) on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) are needed. Existing estimates use clinician-rated anchors in clinically diagnosed Alzheimer's disease (AD) populations. Incorporating the care partner perspective offers important insights, and evaluating biomarker-confirmed cohorts aligns estimates with ongoing trials. METHODS: Anchor-based analyses were conducted to evaluate MWPC on the CDR-SB in early AD (Tauriel; NCT03289143) using Caregiver Global Impression of Change in memory or daily activities. RESULTS: Across time points and anchors, mean CDR-SB changes associated with the "somewhat worse" category ranged from 1.50 to 2.12 in early AD, 1.07 to 2.06 in mild cognitive impairment-AD, and 1.79 to 2.25 in mild AD. DISCUSSION: The proposed ranges are appropriate to define meaningful progression on the CDR-SB in similar cohorts and support the interpretation of treatment benefit through MWPC analyses. Thresholds should be calibrated to the context of use; lower/higher thresholds may be applicable in studies of earlier/later disease over shorter/longer durations. Highlights center dot Within-patient CDR-SB change thresholds are provided using caregiver-rated anchors. center dot 1.5 to 2.5 points may be an appropriate range in early AD trials of similar durations. center dot Cumulative distribution function plots illustrate the benefit of a given treatment. center dot When selecting thresholds, the target population and study design should be considered.
引用
收藏
页码:5889 / 5900
页数:12
相关论文
共 28 条
  • [1] Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials
    Coley, Nicola
    Andrieu, Sandrine
    Jaros, Mark
    Weiner, Michael
    Cedarbaum, Jesse
    Vellas, Bruno
    ALZHEIMERS & DEMENTIA, 2011, 7 (06) : 602 - 610
  • [2] Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials
    Muralidharan, Kumar Kandadi
    Kowalski, Kenneth G. G.
    Tong, Xiao
    Haeberlein, Samantha Budd
    Rajagovindan, Rajasimhan
    Nestorov, Ivan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (01) : 45 - 62
  • [3] Urinary incontinence in Alzheimer's disease is associated with Clinical Dementia Rating-Sum of Boxes and Barthel Activities of Daily Living
    Na, Hae Ri
    Park, Moon Ho
    Cho, Sung Tae
    Lee, Byung Chul
    Park, Suyeol
    Kim, Khae Hawn
    Choi, Jong Bo
    ASIA-PACIFIC PSYCHIATRY, 2015, 7 (01) : 113 - 120
  • [4] Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative
    Samtani, Mahesh N.
    Raghavan, Nandini
    Novak, Gerald
    Nandy, Partha
    Narayan, Vaibhav A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 929 - 952
  • [5] Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials
    Cedarbaum, Jesse M.
    Jaros, Mark
    Hernandez, Chito
    Coley, Nicola
    Andrieu, Sandrine
    Grundman, Michael
    Vellas, Bruno
    ALZHEIMERS & DEMENTIA, 2013, 9 (01) : S45 - S55
  • [6] Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores
    Williams, Monique M.
    Storandt, Martha
    Roe, Catherine M.
    Morris, John C.
    ALZHEIMERS & DEMENTIA, 2013, 9 (01) : S39 - S44
  • [7] Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials (vol 50, pg 45, 2023)
    Muralidharan, Kumar Kandadi
    Kowalski, Kenneth G. G.
    Tong, Xiao
    Haeberlein, Samantha Budd
    Rajagovindan, Rajasimhan
    Nestoro, Ivan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (02) : 145 - 145
  • [8] Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials
    Kumar Kandadi Muralidharan
    Kenneth G. Kowalski
    Xiao Tong
    Samantha Budd Haeberlein
    Rajasimhan Rajagovindan
    Ivan Nestorov
    Journal of Pharmacokinetics and Pharmacodynamics, 2023, 50 : 45 - 62
  • [9] Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials
    Kumar Kandadi Muralidharan
    Kenneth G. Kowalski
    Xiao Tong
    Samantha Budd Haeberlein
    Rajasimhan Rajagovindan
    Ivan Nestoro
    Journal of Pharmacokinetics and Pharmacodynamics, 2023, 50 : 145 - 145
  • [10] Validation of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease
    Rick, J.
    Xie, S.
    Mamikonyan, E.
    Deck, B.
    Rudovsky, S.
    Chen-Plotkin, A.
    Dahodwala, N.
    Morley, J.
    Duda, J.
    Trojanowski, J.
    Weintraub, D.
    MOVEMENT DISORDERS, 2019, 34